Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-10-30 |
Poxel (France) Sumitomo Dainippon Pharma (Japan) |
imeglimin |
type 2 diabetes |
development - commercialisation |
Metabolic diseases |
Development agreement |
2017-10-26 |
Wave LIfe Sciences (USA - MA) |
manufacturing facility and office space in Lexington |
|
opening of new premises |
Rare diseases - Genetic diseases |
Opening of new premises |
2017-10-25 |
Gensight Biologics (France) |
chief medical officer |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
2017-10-25 |
Poietis (France) BASF (Germany) |
3D bioprinting technology for advanced skin care applications |
|
collaboration |
Technology - Services |
Collaboration agreement |
2017-10-24 |
BioInvent (Sweden) |
chief executive officer |
|
resignation |
Cancer - Oncology |
Resignation |
2017-10-23 |
Basilea Pharmaceutica (Switzerland) Astellas Pharma (Japan) |
Cresemba® (isavuconazole) |
aspergillosis, invasive mucormycosis |
development - licensing - commercialisation - promotion |
Infectious diseases |
Milestone |
2017-10-23 |
VBL Therapeutics (Israel) |
gene therapy manufacturing plant in Modiin |
|
opening of new premises |
Cancer - Oncology - Technology - Services |
Opening of new premises |
2017-10-23 |
Adaptimmune (UK) |
vice-president |
|
nomination |
Cancer - Oncology - Autoimmune diseases |
Nomination |
2017-10-23 |
Cytosen Therapeutics (USA - TX) |
member of the scientific and medical advisory board |
|
nomination |
Cancer - Oncology |
Nomination |
2017-10-19 |
Merck KGaA (Germany) |
Carlsbad facility |
|
opening of new premises |
Technology - Services |
Opening of new premises |
2017-10-19 |
Pharmaxis (Australia) |
|
|
nomination |
Fibrotic diseases - Inflammatory diseases |
Nomination |
2017-10-19 |
apceth (Germany) DCPrime (The Netherlands) |
cancer vaccines based on DCPrime’s technology platform DCOne® |
|
manufacturing - production |
Cancer - Oncology |
Production agreement |
2017-10-18 |
Arbutus Biopharma (Canada) Gritstone Oncology (USA - CA) |
lipid nanoparticle (LNP) technology |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2017-10-18 |
Protalix BioTherapeutics (Israel) Chiesi Farmaceutici (Italy) |
pegunigalsidase alfa (PRX-102 - alpha-galactosidase-A) |
Fabry disease |
development - commercialisation |
Rare diseases - Genetic diseases |
Development agreement |
2017-10-16 |
Aimmune Therapeutics (USA - CA) Regeneron Pharmaceuticals (USA - NY) Sanofi (France) |
AR101 and dupilumab |
peanut allergy |
clinical research |
Allergic diseases |
Clinical research agreement |
2017-10-12 |
Bavarian Nordic (Denmark) SGS (Switzerland) |
universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV |
Respiratory Syncytial Virus (RSV) infection |
collaboration |
Infectious diseases |
Collaboration agreement |
2017-10-11 |
Merck KGaA (Germany) |
Life Science Center in Burlington |
|
opening of new premises |
Technology - Services |
Opening of new premises |
2017-10-10 |
Blueprint Medicines (USA - MA) |
vice-president |
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
2017-10-06 |
Amicus Therapeutics (USA - NJ) |
VP business and corporate development |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-10-05 |
Medivir (Sweden) AMR Centre (UK) |
metallo-?-lactamase inhibitor (MBLI) program |
beta lactamase resistant infections |
licensing |
Infectious diseases |
Licensing agreement |